Zacks Investment Research on MSN
INCY's phase III Monjuvi study meets key goals in first-line lymphoma
Incyte INCY announced positive top-line results from a late-stage lymphoma study of Monjuvi/Minjuvi (tafasitamab), a ...
During a live event, Matthew Lunning, DO, interpreted long-term outcomes of the ZUMA-7 and TRANSFORM trials.
Incyte today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 ...
Incyte (Nasdaq: INCY) said the European Commission has approved Minjuvi (tafasitamab) in combination with lenalidomide and rituximab for adult patients with relapsed or refractory follicular lymphoma, ...
Detailed price information for GT Biopharma Inc (GTBP-Q) from The Globe and Mail including charting and trades.
Cells actively help to capture and incorporate influenza viruses. Here, a cell is shown, with a virus in the center of the image. Credit: Emma Hyde / ETH Zurich Scientists have captured an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback